Reverse Transcriptase Inhibitors
This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in the URMC Research Network by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publication.
Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.
-
Wang J, Zhang G, Bambara RA, Li D, Liang H, Wu H, Smith HM, Lowe NR, Demeter LM, Dykes C. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection. J Virol. 2011 Oct; 85(20):10861-73.
-
Wang J, Bambara RA, Demeter LM, Dykes C. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol. 2010 Sep; 84(18):9377-89.
-
von Wyl V, Ehteshami M, Symons J, Bürgisser P, Nijhuis M, Demeter LM, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis. 2010 Apr 1; 201(7):1054-62.
-
Ma Q, Forrest A, Rosenkranz SL, Para MF, Yarasheski KE, Reichman RC, Morse GD. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos. 2008 Mar; 29(2):91-101.
-
Jamburuthugoda VK, Santos-Velazquez JM, Skasko M, Operario DJ, Purohit V, Chugh P, Szymanski EA, Wedekind JE, Bambara RA, Kim B. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J Biol Chem. 2008 Apr 4; 283(14):9206-16.
-
Gao L, Hanson MN, Balakrishnan M, Boyer PL, Roques BP, Hughes SH, Kim B, Bambara RA. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J Biol Chem. 2008 Apr 4; 283(14):9196-205.
-
Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23.
-
Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007 Jan 30; 21(3):325-33.
-
Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Lertora JJ. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007 Feb; 81(2):222-7.
-
Domaoal RA, Bambara RA, Demeter LM. HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies. J Acquir Immune Defic Syndr. 2006 Aug 1; 42(4):405-11.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
